Hans Hammers, MD

Laura Sanza, PhD, MPAS, PA-C, leads a discussion on communicating adverse events with patients and mitigating potential toxicities.

A brief discussion elucidating the patient and caregiver perspectives when selecting a treatment option for renal cell carcinoma.

Comprehensive insight on how best to communicate potential adverse events and followup strategies with patients going on therapy for RCC.

Hans Hammers, MD, PhD, provides a broad overview on the treatment options available to patient who receive a diagnosis of renal cell carcinoma.

The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.

The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.

Expert and patient perspectives on the communication that occurs leading up to and following a diagnosis of renal cell carcinoma.

Healthcare professionals contextualize Terri Blalock’s experience by highlighting the typical presentation of RCC and elucidating workup procedures used to confirm a diagnosis.

Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.

The panel discusses which patients they would consider switching between immunotherapy combination treatments.

Shared insight from Terri Blalock and her caregiver, Kaitlin Blalock, regarding the diagnosis of renal cell carcinoma Terri received following a number of symptoms.

Expert oncologist Hans Hammers, MD, PhD, spearheads an overview on renal cell carcinoma, covering its current incidence and known risk factors.

Experts summarize their most common frontline treatment approaches to advanced RCC.

Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.

The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.

Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.

Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.